Declaration of interest
depression, Anxiety, Psychiatric, pain
FOUNDER
C.L. is on the Clinical Advisory Board for Douglas Pharmaceuticals and has received fees for the following: Janssen Cilag advisory board, Medical Director of Neurostimulation and Interventional Psychiatry at Ramsay Health Care. In the past 36 months, N.G. has received speaker's bureau honoraria from Servier Laboratories, Janssen and Lundbeck, and served on Advisory Boards for Servier Laboratories, Esia, Seqirus and Lundbeck. D.B. is a Director and part owner of Neurotrials Victoria Pty Ltd trading as Neurocentrix and Neurocentrix TMS Pty Ltd; he serves on the advisory board for Eli Lilly and Janssen, and is currently supported by grant funding from Praxis, Janssen, Eli Lilly, Biogen and NHMRC; he has served on speaker panels for Servier, Janssen and Eli Lilly in the past 12 months; he is an investigator on the Janssen Quality of Life Esketamine study. B.T.B. has received grants and served as consultant, advisor or CME speaker for: AstraZeneca, Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Servier, the NHMRC, the Fay Fuller Foundation, and the James and Diana Ramsay Foundation. In the past 3 years, P.F. has received equipment for research from Neurosoft, Nexstim and Brainsway Ltd; he has served on scientific advisory boards for Magstim and LivaNova and received speaker fees from Otsuka; he is a founder and board member for TMS Clinics Australia and Resonance Therapeutics. Within the last 36 months, P.G. has attended a Janssen New Zealand advisory board, and is named on a patent for a controlled release ketamine tablet developed by Douglas Pharmaceuticals. In the past 36 months, D.M. has received research consulting fees from Douglas Pharmaceuticals for a clinical trial involving ketamine. P.B.M. has received remuneration from Janssen (Australia) and Sanofi (Hangzhou) for lectures or advisory board membership within the past 3 years. M.B. has received honoraria EPA Warsaw, Lundbeck, Controversias Barcelona, Servier, Medisquire, HealthEd, ANZJP, European Psychiatric Association, Janssen, Medplan, Milken Institute, Abbott India, ASCP, Allori for Eisai, Otsuka, St Bio Pharma and Sandoz in the past 3 years. G.C. has received educational and travel support from Servier, Astra Zeneca, Otsuka Australia, Merck Sharp & Dohme, and Janssen-Cilag in the past 5 years; he also served on an advisory board for the AFFINITY trial. S.H. has received speaker and consultancy fees from Janssen and Servier, served on advisory boards for Janssen and Lundbeck. A.A.S. is a director of the Australian Medicines Handbook Pty Ltd (unpaid) and has received funding support by the Australian and New Zealand College of Anaesthetists to investigate ketamine for chronic postsurgical pain. K.L. has received contracts for research involving ketamine and other antidepressants and equipment support from ALTO Neuroscience, Cybin and Brainsway; he has received grants/contracts, as well as consulting and manuscript writing fees, from Fisher Wallace, consulting fees (including advisory panel payments and travel funds) from Janssen and consulting fees from Third Bridge; he owns stocks in Validose and has a patent issued for a device developed by the company that could deliver ketamine as well as other drugs; he also owns stocks in Journey Clinical and is a Medical Director for this company; he owns Affective Care, which is a company providing antidepressant treatments, and owns several companies involved in medical care, including depression treatment (Psychiatric Care, Anxiety Psychiatry, Marham and Sol2rise); companies owned by him own equity in Woolsey Pharmaceuticals, Enalare Therapeutics and Cecilia Health. D.G. is the founder and director of TMS Gold Coast and Synergy Specialist Clinic in Gold Coast, Australia. N.L.R.T. has received payment from Janssen for consulting services and participation in an advisory panel. W.M.M. was the uncompensated chair of the DSMB for the MED KET study under review; he is on the board of and has received travel support from Skyland Trail; he is on the Board of 3Keys and is a paid consultant for Signant Health and Sage Therapeutics; he has received past funding from Soterix, Neuronetics, NeoSync and Cervel Neurotherapeutics. P.B. has received speaker fees from Servier and Janssen, educational support from Servier and Lundbeck, is on an advisory board for Incite Health, has been a consultant for Servier, inhaleRx and Greenhorn industries, and has served as DSMC Chair for Douglas Pharmaceuticals. P.E.H. has received consulting fees from Abbott and payment for expert testimony from Ficksman & Conley, LLP, Harry S. Cohen & Associates, Cole, Scott and Kissane, PA, and Shaw Science Partners Inc. F.A.K. has patents as an inventor through the Medical University of South Carolina on fMRI Detection of Deception, with patents pending for Guided rTMS Inhibition of Deception and Optimizing VNS dose with rTMS; he receives loan equipment from Neuronetics and NIRx. P.R.-P. has received honoraria for consulting for Janssen Pharmaceuticals, Abbott Neuromodulation and LivaNova Inc.